ICU admission rates declined for adult CAR-T cell therapy patients at eight U.S. cancer centers between January 2018 and September 2023, according to a study published Dec. 30 in Critical Care Medicine.
Here are three notes from the study:
- ICU admission data was analyzed from eight health systems: New York City-based Memorial Sloan Kettering Cancer Center, Baltimore-based Johns Hopkins University, Houston-based University of Texas MD Anderson Cancer Center, Rochester, Minn.-based Mayo Clinic, Buffalo, N.Y.-based Roswell Park Comprehensive Cancer Center, University of Pittsburgh Medical Center, St. Louis-based Washington University School of Medicine and Cleveland Clinic.
- Between 2018 and 2023, ICU admission rates among CAR-T cell patients declined from 38.5% to 16.4%, while the number of patients treated with CAR-T cells increased annually.
- Compared to 2018, patients admitted to the ICU in 2023 were older, had higher comorbidity indices and more severe toxicities.
Read the full study here.
At the Becker's Perioperative Summit, taking place September 14–15 in Chicago, perioperative leaders and healthcare executives will focus on improving operating room efficiency, enhancing patient safety, optimizing staffing and driving innovation across surgical services. Apply for complimentary registration now.
